Summary
Samenvatting Moleculaire Oncologie
- Course
- Institution
Dit is een samenvatting van de lessen van Moleculaire Oncologie voor de masters Moleculaire mechanismen van ziekten en Klinisch wetenschappelijk onderzoek.
[Show more]
Seller
Follow
BMWstudent19
Reviews received
Content preview
MOLECULAIRE ONCOLOGIEINHOUDSOPGAVE
1.1 Inleiding...................................................................................................................................................... 6
1.1.1 Hallmarks of cancer ............................................................................................................................... 6
1.1.2 Kankerbehandeling ................................................................................................................................ 6
1.2 Doelgerichte kankerbehandeling ............................................................................................................... 7
1.2.1 Algemeen: definitie ............................................................................................................................... 7
1.2.2 Voorbeelden van doelgerichte therapie ................................................................................................ 8
1.2.2.1 Hormonale therapie ...................................................................................................................... 8
1.2.2.2 Behandelingen gericht op intracellulaire signaaltransductie ....................................................... 9
1.2.2.3 Monoklonale antilichamen (mAb) .............................................................................................. 10
1.2.2.4 Tyrosinekinase inhibitoren (TKI’s) ............................................................................................... 11
1.2.2.5 Antiangiogene therapie .............................................................................................................. 11
1.2.3 Uitdagingen van doelgerichte therapie ............................................................................................... 12
1.3 Voorbeeld: de EGFR-pathway als aangrijpingspunt ................................................................................. 12
1.3.1 Algemeen: de EGFR pathway............................................................................................................... 12
1.3.2 Anti-EGFR therapie .............................................................................................................................. 13
1.3.2.1 Tyrosine kinase inhibitoren (TKI) ................................................................................................ 13
1.3.2.2 Monoklonale antilichamen ......................................................................................................... 14
1.4 Biomerkers ............................................................................................................................................... 14
1.4.1 Types biomerkers ................................................................................................................................ 14
1.4.1.1 Biomerker voor aanleg ................................................................................................................ 15
1.4.1.2 Screeningsbiomerker .................................................................................................................. 15
1.4.1.3 Diagnostische biomerker ............................................................................................................ 15
1.4.1.4 Prognostische biomerker ............................................................................................................ 16
1.4.1.5 Predictieve biomerker ................................................................................................................ 16
1.4.1.6 Farmacodynamische biomerker ................................................................................................. 16
1.4.1.7 Herval biomerker ........................................................................................................................ 17
1.4.1.8 Uitdagingen ................................................................................................................................. 17
1.4.2 EGFR en KRAS als biomerker ............................................................................................................... 17
1.4.2.1 EGFR ............................................................................................................................................ 18
1.4.2.2 KRAS ............................................................................................................................................ 18
2.1 HIF activeert angiogene factoren ............................................................................................................. 20
2.1.1 Hypoxie-induceerbare factor 1 (HIF 1) ................................................................................................ 20
2.1.2 HIF 1 activeert angiogene factoren ..................................................................................................... 21
1
,2.2 De vorming van nieuwe bloedvaten d.m.v. sprouting ............................................................................. 22
2.2.1 Het proces van ‘sprouting’................................................................................................................... 22
2.2.2 De ‘tip’cel ............................................................................................................................................. 22
2.2.2.1 De ‘tip’cel .................................................................................................................................... 22
2.2.2.2 Selectie van de ‘tip’cel ................................................................................................................ 22
2.2.2.3 Laterale inhibitie door Dll4/Notchsignalisatie ............................................................................ 23
2.2.2.4 Invasie van de ‘tip’cel .................................................................................................................. 23
2.2.3 De ‘stalk’cel.......................................................................................................................................... 23
2.2.3.1 De ‘stalk’cel ................................................................................................................................. 23
2.2.3.2 Elongatie van de ‘stalk’cel ........................................................................................................... 23
2.2.3.3 Rol van VEGFR-1 (Flt 1) in de ‘stalk’cellen ................................................................................... 24
2.2.3.4 ‘Stalk’cellen en de vorming van een lumen ................................................................................ 24
2.2.4 De ‘falanx’cel ....................................................................................................................................... 24
2.2.5 Maturatie van het gevormde bloedvat ............................................................................................... 24
2.3 Hypoxie veroorzaakt een abnormale tumorvasculatuur ......................................................................... 25
2.4 Antiangiogene middelen in de behandeling van kanker .......................................................................... 25
2.4.1 Inhibitie van angiogenese via VEGF ..................................................................................................... 25
2.4.2 Successen van anti-VEGF therapie ...................................................................................................... 26
2.4.3 Uitdagingen van anti-VEGF therapie ................................................................................................... 26
2.5 Normalisatie van de tumorvasculatuur ................................................................................................... 26
2.6 Bijkomende mechanismen die leiden tot verhoogde bloedtoevoer ....................................................... 28
2.6.1 ‘Intussusceptive’ microvasculaire groei ............................................................................................... 28
2.6.2 Vasculaire co-optie .............................................................................................................................. 28
2.6.3 Vasculogenese: rol van EPC’s in tumor neovascularisatie ................................................................... 29
2.6.4 Vasculogene ‘mimicry’ ......................................................................................................................... 29
2.6.5 Rol van kankerstamcellen in tumor neovascularisatie ........................................................................ 29
3.1 Inleiding.................................................................................................................................................... 30
3.2 DNA methylatie ........................................................................................................................................ 31
3.3 Histon modificaties .................................................................................................................................. 32
3.3.1 Histon modificatie mechanismen ........................................................................................................ 32
3.3.2 Interactie epigenetica .......................................................................................................................... 33
3.3.3 Tumor initiatie ..................................................................................................................................... 33
3.3.4 Epigenetische landschap in kanker ...................................................................................................... 34
3.3.5 Interactie genetica – epigenetica ........................................................................................................ 35
3.4 MicroRNA’s .............................................................................................................................................. 36
3.5 Technieken ............................................................................................................................................... 37
3.5.1 Bisulfiet behandeling ........................................................................................................................... 37
2
, 3.5.2 PCR ....................................................................................................................................................... 37
3.5.3 Pyrosequencing ................................................................................................................................... 38
3.5.4 array..................................................................................................................................................... 38
3.5.5 NGS ...................................................................................................................................................... 39
3.6 Therapie ................................................................................................................................................... 40
4.1 Inleiding.................................................................................................................................................... 41
4.2 Technieken ............................................................................................................................................... 42
4.2.1 Next generation sequencing ................................................................................................................ 42
4.2.2 Microarray ........................................................................................................................................... 42
4.2.2.1 Microarray – SNP ........................................................................................................................ 42
4.2.2.2 Microarray – methylatie ............................................................................................................. 43
4.2.2.3 Microarray – genexpressie.......................................................................................................... 43
4.3 Databases ................................................................................................................................................. 44
4.3.1 The cancer genome atlas ..................................................................................................................... 44
4.3.2 Gene Expression Omnibus ................................................................................................................... 44
4.3.3 Cosmic ................................................................................................................................................. 44
4.3.4 ICGC ..................................................................................................................................................... 44
4.4 Wat doen we met deze data? .................................................................................................................. 45
4.4.1 Classificatie van CRC ............................................................................................................................ 45
4.4.2 Voorbeeld uit het lab: biomerker onderzoek ...................................................................................... 46
5.1 Companion diagnostics (CDx) for precision medicine: tissue and body fluid analysis ............................. 47
5.1.1 General concepts ................................................................................................................................. 47
5.1.1.1 Precision medicine ...................................................................................................................... 47
5.1.1.2 Companion diagnostics ............................................................................................................... 47
5.1.1.3 Types biomerkers ........................................................................................................................ 48
5.1.2 Technieken .......................................................................................................................................... 49
5.1.2.1 Histologische technieken ............................................................................................................ 49
5.1.2.2 Moleculaire technieken .............................................................................................................. 51
5.1.3 Considerations ..................................................................................................................................... 52
5.1.4 Liquid biopsy ........................................................................................................................................ 54
5.2 Moleculaire pathologie ............................................................................................................................ 55
6.1 Drug development proces........................................................................................................................ 57
6.1.1 Drug discovery and development timeline ......................................................................................... 57
6.1.2 Het proces............................................................................................................................................ 57
6.1.3 GCP ...................................................................................................................................................... 57
6.2 Ontwikkeling van geneesmiddelen: Een onderneming met een hoog risico ........................................... 58
6.3 Clinical trials ............................................................................................................................................. 58
3
, 6.3.1 Verloop ................................................................................................................................................ 58
6.3.2 Fase 1 proefopzetten ........................................................................................................................... 59
6.3.2.1 Dosislimiterende toxiciteit (DLT)................................................................................................. 60
6.3.2.2 Andere termen ............................................................................................................................ 60
6.3.2.3 Startdoses voor fase 1 trials ........................................................................................................ 61
6.3.2.4 Target population van fase 1 non-oncology studies ................................................................... 62
6.3.3 Response Evaluation ............................................................................................................................ 62
7.1 Introductie ............................................................................................................................................... 64
7.2 Concept van immuunontwijking .............................................................................................................. 64
7.2.1 Concept................................................................................................................................................ 64
7.2.2 Bewijzen van interactie ....................................................................................................................... 64
7.2.3 Belangrijke immuuncellen betrokken bij de antitumor immuunrespons............................................ 65
7.3 Kanker immunotherapie .......................................................................................................................... 65
7.3.1 T-cellen ................................................................................................................................................ 65
7.3.1.1 Signaal 1: specificiteit.................................................................................................................. 66
7.3.1.2 Signaal 2: activatie of remming................................................................................................... 67
7.3.1.3 Signaal 3: differentiatie ............................................................................................................... 67
7.4 Immuunontwijkingsmechanismen van tumorcellen ................................................................................ 68
7.5 Immuun checkpoint blockers ................................................................................................................... 68
7.6 Hoe weerstand overwinnen? ................................................................................................................... 69
8.1 Introductie ............................................................................................................................................... 71
8.1.1 Oorsprong en afstamming van NK-cellen ............................................................................................ 71
8.1.2 Een overvloed aan receptoren ............................................................................................................ 72
8.2 CD16 en antilichaam-afhankelijke cellulaire cytotoxiciteit (ADCC) .......................................................... 72
8.3 Cytokine stimulatie .................................................................................................................................. 73
8.3.1 De IL-2 ‘common γ chain’ cytokine familie .......................................................................................... 73
8.3.2 IL-15 modificaties ................................................................................................................................ 73
8.4 Resistentie tegen immunosuppressie ...................................................................................................... 74
8.4.1 Gene editing ........................................................................................................................................ 74
8.4.2 TGFβRII KO ........................................................................................................................................... 75
8.5 Manieren om NK-celtherapie te verbeteren ........................................................................................... 75
8.5.1 Checkpoint blokkade ........................................................................................................................... 75
8.5.2 Non-self (celtherapie) .......................................................................................................................... 75
8.5.3 chimeric antigen receptors .................................................................................................................. 76
8.5.4 BiKE, BiTE and TriKE ............................................................................................................................. 76
9.1 De basiskenmerken van kanker ............................................................................................................... 77
9.1.1 De levensloop van kankercellen .......................................................................................................... 77
4
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller BMWstudent19. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $10.34. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
76462 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now